Skip to main content

James E. Dentzer

Equibles does not estimate personal net worth.

Get an email with a short summary when Curis Inc publishes a filing, an earnings call transcript or a press release.

Get CRIS alerts

About James E. Dentzer

James E. Dentzer is recorded as Board Member at Curis Inc (CRIS) since May 27, 2021 and CEO at Curis Inc (CRIS). The newest filing on record that lists James E. Dentzer as CEO and Board Member at Curis Inc (CRIS) is dated April 21, 2026. Curis Inc reported in an 8-K filed May 23, 2024 a re-election or new board role (Class I director) for James E. Dentzer, on the board since at least 2021, effective May 21, 2024. The proxy statement of Curis Inc reports total compensation of $3,390,187 for James E. Dentzer in fiscal 2021, including a base salary of $590,212. Disclosed compensation is on record for 5 fiscal years. James E. Dentzer has spoken on 9 earnings calls across 1 company, most recently for Curis Inc on May 12, 2026. Curis Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Curis Inc includes Martyn D. Greenacre (Chairman and Board Member), William E. Steinkrauss (CFO), Anne E. Borgman (Board Member) and 7 others.

“The following nominees were elected to the Company's Board of Directors (the "Board") as Class I directors for terms of three years expiring at the 2027 annual meeting of stockholders: James E. Dentzer”
Curis Inc Form 8-K, filed May 23, 2024 · Read the filing

James E. Dentzer on recent calls

“We continue to make steady progress in our Take Aim lymphoma study in primary CNS lymphoma, one of the most rare and most difficult to treat of the NHL subtypes.”
CEO, Curis Inc Q1 FY2026 Earnings Call ·
“We continue to make steady progress in our TakeAim lymphoma study in primary CNS lymphoma, One of the most rare and most difficult to treat of the NHL subtypes.”
CEO, Q4 FY2025 Earnings conference call (announced in 8-K) ·
“We continue to make steady progress in our TakeAim Lymphoma study, which is evaluating emavusertib in combination with ibrutinib in patients with primary CNS lymphoma, one of the most rare and most difficult to treat of the NHL subtypes.”
CEO, Curis Inc Q3 FY2025 Earnings Call ·
“We continue to make steady progress in our TakeAim Lymphoma study, which is evaluating emavusertib in combination with ibrutinib in patients with PCNSL.”
CEO, Curis Inc Q2 FY2025 Earnings Call ·
“This quarter, we made significant progress in advancing emavusertib in our three key areas of focus: first, as a monotherapy in patients with relapsed/refractory AML with a FLT3 or splicing factor mutation in our TakeAim Leukemia study; second, as a doublet therapy for patients with relapsed/refractory primary CNS…”
CEO, Curis Inc Q1 FY2024 Earnings Call ·

Affiliation history

  • Curis Inc (CRIS)

    Board Member

    Proxy statement

    Current

    2021-05-27–present

    Last confirmed April 21, 2026

  • Curis Inc (CRIS)

    CEO

    Proxy statement

    Current

    Start not stated–present

    Last confirmed April 21, 2026

Company network

Leadership on record at Curis Inc

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2021 Curis Inc (CRIS) $590,212 $3,390,187
2020 Curis Inc (CRIS) $554,900 $1,672,849
2019 Curis Inc (CRIS) $509,507 $1,557,773
2018 Curis Inc (CRIS) $479,383 $1,964,736
2017 Curis Inc (CRIS) $442,652 $1,578,961

Recent activity